Welcome to Tech Beat, your daily read on the technology shaping our world.
DeepSeek has done it again. Hours after OpenAI launched GPT five point five, the Chinese lab dropped its latest model — and the pricing is staggering. The pro version costs roughly ninety-eight percent less than OpenAI's equivalent, reigniting questions about whether American AI companies can sustain their premium positioning in an increasingly crowded market.
On a quieter but potentially more consequential front, Isomorphic Labs — the DeepMind spinoff — announced at WIRED Health in London that its AI-designed drug candidates are heading into human trials. President Max Jaderberg described a broad and exciting pipeline of new medicines, marking a genuine milestone in the long-promised marriage of machine learning and pharmaceutical discovery.
And a security alert worth flagging for anyone in government IT: the Cybersecurity and Infrastructure Security Agency has given federal agencies two weeks to patch a Microsoft Defender zero-day called BlueHammer. The vulnerability was disclosed in early April by a disgruntled researcher, alongside two additional bugs, and the clock is now running on remediation.
Three very different stories today — price wars, potential cures, and a patching deadline — all reminding us that the stakes in technology rarely stay abstract for long. Keep surfing. Tech Beat out.
